Abstract
In previous studies, we showed that immunization with 2.5 mg of BEC2, an anti-idiotypic MAb that mimics GD3 ganglioside, can induce antibodies against GD3 in approximately 25% of patients. In this trial, 50 melanoma patients at high risk for recurrence were randomly assigned to one of the five BEC2 dose levels (2.5 microg-10mg) to determine if lower or higher BEC2 doses are more immunogenic. We also tested whether prolonged booster immunizations can enhance the anti-GD3 antibody response. All patients developed detectable IgG against BEC2 except for one patient at the lowest BEC2 dose level. Six patients developed detectable antibody responses to GD3, all of them at the lower three dose levels of BEC2. We conclude that high doses of BEC2 are not necessary to induce anti-GD3 antibody responses and that lower doses may be more immunogenic than the 2.5 mg dose used in previous BEC2 trials. Prolonged booster immunizations did not induce or maintain antibody responses.
References
May 30, 1991·International Journal of Cancer. Journal International Du Cancer·G RitterP Livingston
Jul 1, 1991·The Journal of Clinical Investigation·P B Chapman, A N Houghton
Dec 1, 1990·The Journal of Clinical Investigation·A MittelmanZ Arlin
May 15, 1985·International Journal of Cancer. Journal International Du Cancer·T TaiD L Morton
Feb 1, 1997·Hybridoma·L G DurrantR A Robins
Aug 1, 1997·Melanoma Research·M L NasiP B Chapman
Citations
Aug 17, 2012·Future Oncology·Catherine RabuLindy Durrant
Jul 20, 2010·Immunotherapy·Beatrix KotlanFrancesco M Marincola
Mar 15, 2006·Journal of Immunotherapy·Marcelo D GuthmannLeonardo Fainboim
Jun 23, 2009·Cancer Biotherapy & Radiopharmaceuticals·Robert O DillmanKanoe Allen
Mar 2, 2011·Cancer Biotherapy & Radiopharmaceuticals·Robert O Dillman
Sep 5, 2008·Expert Review of Vaccines·Lee B Riley, Sanjiv S Agarwala
Jun 23, 2011·Expert Review of Vaccines·Oliver KleinJonathan Cebon
May 1, 2009·Human Immunology·Marta E PolakIan A Cree
Feb 5, 2008·Biochimica Et Biophysica Acta·Takao TakiJacques Portoukalian
Nov 2, 2007·Vaccine·Lothar H FinkeAxel Hoos
Aug 6, 2005·IUBMB Life·Florence Malisan, Roberto Testi
Nov 13, 2010·Cancer Science·Angelita S RamosJane Z de Moraes
Jan 19, 2008·Cytotherapy·J-E ParkP B Chapman
Mar 5, 2013·Human Vaccines & Immunotherapeutics·Chizuru Ogi, Atsushi Aruga
Jul 30, 2014·Frontiers in Immunology·Thomas Kieber-EmmonsRamachandran Murali
Oct 10, 2006·Veterinary Immunology and Immunopathology·R J MilnerJ Farese
Sep 30, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Giuseppe GiacconeCatherine Legrand
Jun 3, 2005·Nature Reviews. Drug Discovery·Danielle H Dube, Carolyn R Bertozzi
Jul 26, 2013·Proceedings of the Japan Academy. Series B, Physical and Biological Sciences·Takao Taki
Oct 8, 2009·Alternatives to Laboratory Animals : ATLA·Jarrod Bailey
Jun 6, 2006·The Journal of Immunology : Official Journal of the American Association of Immunologists·Martina M Uttenreuther-FischerPeter Fischer
Jul 23, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Paul B ChapmanPhilip O Livingston